Adial Pharmaceuticals (ADIL) Total Liabilities (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Total Liabilities of $1.5 million for Q1 2026, up 8.1% sequentially from $1.4 million in Q4 2025, and up 14.01% YoY from $1.3 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Total Liabilities (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Total Liabilities for 10 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Total Liabilities rose 14.01% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 14.01% YoY) and the FY2025 annual result came in at $1.4 million, up 43.15% from the prior year.
- Total Liabilities advanced to $1.5 million in Q1 2026 per ADIL's latest filing, from $1.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $3.3 million in Q1 2022 and troughed at $461752.0 in Q2 2023.
- A 5-year average of $1.5 million and a median of $1.2 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities slumped 84.41% in 2023, then jumped 135.36% in 2025.
- Over 5 years, Total Liabilities stood at $2.5 million in 2022, then tumbled by 73.41% to $653076.0 in 2023, then soared by 49.42% to $975858.0 in 2024, then surged by 43.15% to $1.4 million in 2025, then advanced by 8.1% to $1.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.5 million, $1.4 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 28.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 975,858.00 |
| Sep 30, 2024 | 829,046.00 |
| Jun 30, 2024 | 671,882.00 |
| Mar 31, 2024 | 562,731.00 |
| Dec 31, 2023 | 653,076.00 |
| Sep 30, 2023 | 528,179.00 |
| Jun 30, 2023 | 461,752.00 |
| Mar 31, 2023 | 2.46 Mn |
| Dec 31, 2022 | 2.46 Mn |
| Sep 30, 2022 | 2.33 Mn |
| Jun 30, 2022 | 2.96 Mn |
| Mar 31, 2022 | 3.26 Mn |
| Dec 31, 2021 | 3.97 Mn |
| Sep 30, 2021 | 3.25 Mn |
| Jun 30, 2021 | 3.23 Mn |